Home / Health / Novo Nordisk Pill Shows Promise for Diabetic Youth
Novo Nordisk Pill Shows Promise for Diabetic Youth
23 Apr
Summary
- Oral GLP-1 drug significantly lowered blood sugar in children.
- Trial met main goal, showing statistically significant results.
- Drugmaker plans regulatory approval application in 2026.
A late-stage trial for Novo Nordisk's oral GLP-1 drug has successfully met its main goal. The medication significantly reduced blood sugar levels in children and adolescents diagnosed with type 2 diabetes. This pivotal study involved 132 patients aged 10 to 17 over a 26-week period.
The trial results showed that patients treated with the oral drug experienced an average reduction in blood sugar levels that was 0.83 percentage points greater than those receiving a placebo. This difference was confirmed as statistically significant by the drugmaker.
This marks the first time an oral GLP-1 therapy has been tested in young individuals. Type 2 diabetes is increasingly prevalent in younger populations, with limited treatment options available beyond metformin and insulin. Metformin proves ineffective for many adolescents, while insulin poses risks.
Novo Nordisk plans to submit applications for regulatory approval in the United States and the European Union during the latter half of 2026. Positive outcomes in this trial could expand the use of Novo Nordisk's semaglutide treatments beyond adults and solidify its market position.
